

Online Supplement

Supplementary Tables

Table S1 – Number of SNPs used to calculate the PRS for each cancer type

Table S2 - Definition of lifestyle factors

Table S3 – Definition of additional covariates included in further statistical models

Table S4 - Adjusted associations between the Healthy Lifestyle Index, Polygenic Risk Score, and cancer risk

Table S5 – Relative excess risk due to interaction (RERI) for additive interactions between Healthy Lifestyle Index and Polygenic Risk Score for overall cancer and 13 cancer types

Table S1 – Number of SNPs used to calculate the PRS for each cancer type

Cancer Type	Number of SNPs used in PRS calculation
Prostate	161
Colorectal	103
Breast	187
Lung	109
Melanoma	24
Non-Hodgkin lymphoma	19
Kidney	19
Uterine	9
Pancreatic	22
Bladder	15
Oral cavity/pharynx	14
Ovarian	36
Lymphocytic leukaemia	75

SNP – single nucleotide polymorphism; PRS – polygenic risk score

Table S2 - Definition of lifestyle factors

Lifestyle factor	Measure	Classification	
Be a healthy weight	BMI (kg/m ²)	18.5 to <25	0.5
		25 to <30	0.25
		<18.5 or ≥30	0
	Waist circumference (cm) ^a	Men: <94; Women: <80	0.5
		Men: 94 to <102; Women: 80 to <88	0.25
		Men: ≥102; Women: ≥88	0
Be physically active	Physical activity (MET-mins/week) ^b	≥3000	1
		600 to <3000	0.5
		<600	0
Eat a diet rich in wholegrains, vegetables, fruit, and beans	Fruit and vegetable intake (serves/day)	≥5	0.5
		3 to <5	0.25
		<3	0
		(1 serve = 1 piece fresh fruit, 5 pieces dried fruit, or 3 heaped tablespoons of cooked or raw vegetables)	
	Wholegrain intake (serves/day)	≥5.5	0.5
		>2 to <5.5	0.25
		≤2	0
		(1 serve = 1 bowl cereal or 1 slice wholemeal or wholegrain bread. Cereal type not considered due to large amount of missingness. Wholegrain intake calculated without cereal type was slightly more correlated with dietary fibre intake from 24 hr diet recall than wholegrain intake calculated with cereal type considered)	
Limit consumption of red and processed meat	Red meat intake (times/week)	<2 times/week	0.5
		2-4 times/week	0.25
		>4 times/week	0
	Processed meat intake (times/week)	<once/week	0.5
		once/week	0.25
		≥twice/week	0
Limit alcohol consumption	Alcohol intake (g/day) ^c	0.0	1
		Males: >0 to ≤28; Females: >0 to ≤14	0.5
		Males: >28; Females: >14	0
Don't smoke	Current Smoking Status	(1 glass champagne/red wine/white wine = 12.8 g, 1 pint of beer = 18.4 g, 1 measure of spirits (25 ml) = 8 g, 1 standard measure of fortified wine (50 ml) = 8 g; 1 glass of other alcoholic drinks (e.g. alcopops) = 12 g. ¹)	
		Never Smoker	1
		Former Smoker	0.5
		Current Smoker	0

^a Those with a waist circumference (WC) < 50 cm were excluded (i.e. WC recoded to missing; n=7)

^b Physical activity calculated as metabolic equivalent (MET)-mins/week using IPAQ short form guidelines² and the self-reported estimated time spent (on a typical day) doing at least 2 of the 3 following activities – walking, moderate physical activity, and vigorous physical activity.

^c Estimated from self-reported frequency of alcohol intake and weekly or monthly quantities of different types of alcoholic beverages consumed. For those missing information on quantity of “other alcoholic drinks”, intake was estimated from the quantities reported for wine, beer, spirits, and fortified wine (n=224 609). For those who reported consuming alcohol less than weekly and had missing data on quantities of different beverage types, scores were estimated from data available (n=1166) or, where there were no data on quantities consumed, a score of 0.5 was allocated (n=73 137).

Table S3 – Definition of additional covariates included in further statistical models

Cancer Type	Additional covariates included in Model 2
Colorectal cancer	Height (cm), history of inflammatory bowel disease, Crohn's disease, or ulcerative colitis (yes/no)
Breast cancer	Height (cm), ever hormone replacement therapy use (yes/no), ever oral contraceptive pill use (yes/no), number of live births, age at onset of menopause (last menstrual period; yes/no), age at menarche (years)
Uterine cancer	Height (cm), ever hormone replacement therapy use (yes/no), number of live births, have had menopause at baseline (yes/no), age at menarche (years)
Kidney cancer	Height (cm)
Lung cancer	History of chronic obstructive pulmonary disease or pulmonary fibrosis (yes/no)
Melanoma	Height (cm), time spent outdoors in summer (hours/day), use of sun/UV protection (never/rarely, sometimes, most of the time, always, do not go out in sunshine), solarium use (yes/no)
Non-Hodgkin lymphoma	History of any of the following autoimmune diseases - Sjogren syndrome, systemic lupus erythematosus, haemolytic anaemia, rheumatoid arthritis, pernicious anaemia, myasthenia gravis, celiac disease, immune thrombocytopenic purpura, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic sclerosis or scleroderma, poly- or dermatomyositis, psoriasis, sarcoidosis, type 1 diabetes (yes/no)
Oral cavity/pharyngeal cancer	Time spent outdoors in summer (hours/day), use of sun/UV protection (never/rarely, sometimes, most of the time, always, do not go out in sunshine)
Ovarian cancer	Height (cm), ever hormone replacement therapy use (yes/no), ever oral contraceptive pill use (yes/no), number of live births, have had menopausal at baseline (yes/no), age at menarche (years), tubal ligation or fallopian tubes removed (yes/no)
Pancreatic cancer	Height (cm)
Prostate cancer	Height (cm)

Table S4 - Adjusted associations between the Healthy Lifestyle Index, Polygenic Risk Score, and cancer risk

Cancer Type	No. of cases/ person-years	Healthy lifestyle index			p _{trend}	Polygenic risk score			
		High	Intermediate	Low		Low	Intermediate	High	p _{trend}
Overall cancer									
Model 1 ^a	15 240/1 926 987	Ref	1.15 (1.11, 1.20)	1.32 (1.26, 1.37)	<0.0001	Ref	1.08 (1.04, 1.13)	1.20 (1.16, 1.25)	<0.0001
Prostate cancer									
Model 1 ^b	4476/981 844	Ref	0.99 (0.91, 1.06)	0.92 (0.86, 0.99)	0.024	Ref	1.30 (1.20, 1.40)	1.89 (1.75, 2.03)	<0.0001
Model 2 ^c	4476/981 844	Ref	0.99 (0.91, 1.06)	0.92 (0.86, 0.99)	0.024	Ref	1.30 (1.20, 1.40)	1.89 (1.75, 2.03)	<0.0001
Colorectal cancer									
Model 1 ^a	2150/1 990 006	Ref	1.14 (1.02, 1.28)	1.42 (1.28, 1.59)	<0.0001	Ref	1.49 (1.33, 1.67)	2.04 (1.82, 2.27)	<0.0001
Model 2 ^d	2150/1 990 006	Ref	1.14 (1.02, 1.28)	1.42 (1.27, 1.58)	<0.0001	Ref	1.49 (1.33, 1.67)	2.04 (1.82, 2.27)	<0.0001
Post-menopausal breast cancer									
Model 1 ^b	1990/576 641	Ref	1.36 (1.22, 1.52)	1.42 (1.27, 1.59)	<0.0001	Ref	1.35 (1.20, 1.52)	1.73 (1.55, 1.94)	<0.0001
Model 2 ^e	1837/537 658	Ref	1.34 (1.20, 1.50)	1.42 (1.26, 1.59)	<0.0001	Ref	1.36 (1.20, 1.53)	1.75 (1.56, 1.96)	<0.0001
Lung cancer									
Model 1 ^a	1256/1 994 812	Ref	1.59 (1.32, 1.93)	3.50 (2.96, 4.15)	<0.0001	Ref	1.30 (1.12, 1.50)	1.64 (1.43, 1.89)	<0.0001
Model 2 ^f	1256/1 994 812	Ref	1.58 (1.30, 1.91)	3.33 (2.81, 3.94)	<0.0001	Ref	1.30 (1.12, 1.50)	1.64 (1.42, 1.88)	<0.0001
Melanoma									
Model 1 ^a	1200/1 994 915	Ref	1.13 (0.98, 1.30)	0.98 (0.85, 1.13)	0.71	Ref	1.37 (1.17, 1.60)	2.03 (1.75, 2.34)	<0.0001
Model 2 ^g	1118/1 844 648	Ref	1.14 (0.98, 1.32)	1.00 (0.86, 1.16)	0.97	Ref	1.39 (1.18, 1.63)	2.06 (1.77, 2.40)	<0.0001
Non-Hodgkin lymphoma									
Model 1 ^a	721/1 997 000	Ref	0.98 (0.82, 1.18)	1.01 (0.84, 1.21)	0.92	Ref	1.20 (1.00, 1.45)	1.42 (1.18, 1.70)	0.0002
Model 2 ^h	721/1 997 000	Ref	0.98 (0.81, 1.18)	1.00 (0.84, 1.20)	0.95	Ref	1.20 (0.99, 1.45)	1.42 (1.18, 1.70)	0.0002

Cancer Type	No. of cases/ person-years	Healthy lifestyle index				Polygenic risk score			
		High	Intermediate	Low	p _{trend}	Low	Intermediate	High	p _{trend}
Kidney cancer									
Model 1 ^a	547/1 997 962	Ref	1.73 (1.36, 2.21)	1.91 (1.51, 2.42)	<0.0001	Ref	1.18 (0.95, 1.47)	1.47 (1.20, 1.81)	0.0002
Model 2 ^c	547/1 997 962	Ref	1.73 (1.36, 2.21)	1.91 (1.51, 2.41)	<0.0001	Ref	1.18 (0.95, 1.47)	1.47 (1.20, 1.81)	0.0002
Uterine cancer									
Model 1 ^b	494/995 300	Ref	1.31 (1.05, 1.65)	1.63 (1.31, 2.04)	<0.0001	Ref	1.60 (1.26, 2.02)	1.87 (1.48, 2.36)	<0.0001
Model 2 ^e	466/826 638	Ref	1.33 (1.05, 1.67)	1.63 (1.29, 2.04)	<0.0001	Ref	1.65 (1.29, 2.11)	1.89 (1.48, 2.40)	<0.0001
Pancreatic cancer									
Model 1 ^a	451/1 998 456	Ref	1.54 (1.18, 2.00)	1.98 (1.54, 2.55)	<0.0001	Ref	1.62 (1.25, 2.09)	2.26 (1.77, 2.89)	<0.0001
Model 2 ^c	451/1 998 456	Ref	1.53 (1.18, 2.00)	1.98 (1.54, 2.54)	<0.0001	Ref	1.62 (1.25, 2.10)	2.26 (1.77, 2.89)	<0.0001
Bladder cancer									
Model 1 ^a	424/1 998 387	Ref	1.23 (0.92, 1.64)	2.03 (1.57, 2.64)	<0.0001	Ref	1.49 (1.16, 1.91)	1.61 (1.26, 2.06)	0.0002
Oral cavity/ pharyngeal cancer									
Model 1 ^a	415/1 998 464	Ref	1.24 (0.94, 1.64)	1.69 (1.31, 2.18)	<0.0001	Ref	1.06 (0.84, 1.35)	1.06 (0.84, 1.35)	0.60
Model 2 ^j	402/1 949 841	Ref	1.21 (0.92, 1.60)	1.60 (1.23, 2.07)	0.0002	Ref	1.06 (0.83, 1.34)	1.07 (0.84, 1.36)	0.59
Ovarian cancer									
Model 1 ^b	315/996 236	Ref	1.13 (0.86, 1.47)	1.04 (0.79, 1.38)	0.75	Ref	1.26 (0.95, 1.68)	1.47 (1.11, 1.94)	0.0065
Model 2 ^k	282/827 032	Ref	1.18 (0.89, 1.56)	1.03 (0.77, 1.40)	0.77	Ref	1.24 (0.92, 1.68)	1.45 (1.09, 1.95)	0.012
Lymphocytic leukaemia									
Model 1 ^a	246/1 999 253	Ref	1.05 (0.76, 1.44)	0.96 (0.70, 1.32)	0.78	Ref	1.13 (0.78, 1.63)	2.45 (1.78, 3.36)	<0.0001

Overall cancer = Overall incident cases of the 13 cancer types assessed in this study

^a Cox proportional hazards regression adjusted for age at baseline, sex, assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, and income

^b Cox proportional hazards regression adjusted for age at baseline, assessment centre, 40 PCs, Townsend Index, education, birth location, and income

^c Cox proportional hazards regression adjusted for covariates in model 1^a + height

^d Cox proportional hazards regression adjusted for covariates in model 1^a + height and history of inflammatory bowel disease

^e Cox proportional hazards regression adjusted for covariates in model 1^b + height, ever hormone replacement therapy use, ever oral contraceptive pill use, number of live births, age of menopause, age at menarche

^f Cox proportional hazards regression adjusted for covariates in model 1^a + history of chronic obstructive pulmonary disease or pulmonary fibrosis

^g Cox proportional hazards regression adjusted for covariates in model 1^a + height, time spent outdoors in summer, use of sun/UV protection, solarium use

^h Cox proportional hazards regression adjusted for covariates in model 1^a + history of autoimmune disease

ⁱ Cox proportional hazards regression adjusted for covariates in model 1^b + height, ever hormone replacement therapy use, number of live births, menopausal status, age at menarche

^j Cox proportional hazards regression adjusted for covariates in model 1^a + time spent outdoors in summer, use of sun/UV protection

^k Cox proportional hazards regression adjusted for covariates in model 1^b + height, ever hormone replacement therapy use, ever oral contraceptive pill use, number of live births, menopausal status, age at menarche, tubal ligation or fallopian tubes removed

Table S5 – Relative excess risk due to interaction (RERI) for additive interactions between Healthy Lifestyle Index and Polygenic Risk Score for overall cancer and 13 cancer types

Healthy Lifestyle Index	Polygenic Risk Score						Overall test for RERI (p-value)
	Intermediate			High			
	RERI	95%CI	p-value	RERI	95%CI	p-value	
Overall cancer							0.049
Intermediate	0.07	-0.05, 0.18	0.24	-0.007	-0.13, 0.11	0.91	
Unfavourable	0.04	-0.07, 0.16	0.45	0.08	-0.04, 0.20	0.17	
Prostate cancer							0.14
Intermediate	0.22	0.007, 0.43	0.043	0.16	-0.08, 0.41	0.20	
Unfavourable	0.06	-0.14, 0.26	0.57	-0.09	-0.33, 0.15	0.46	
Colorectal cancer							<0.0001
Intermediate	0.32	-0.03, 0.67	0.071	0.46	0.08, 0.85	0.017	
Unfavourable	0.25	-0.11, 0.61	0.18	0.61	0.22, 0.99	0.0021	
Post-menopausal breast cancer							0.0001
Intermediate	-0.09	-0.51, 0.33	0.68	0.22	-0.21, 0.65	0.32	
Unfavourable	-0.04	-0.47, 0.39	0.86	0.43	-0.02, 0.88	0.059	
Lung cancer							<0.0001
Intermediate	0.43	-0.08, 0.94	0.098	0.53	-0.009, 1.08	0.054	
Unfavourable	1.21	0.60, 1.82	0.0001	1.96	1.25, 2.67	<0.0001	
Melanoma							0.40
Intermediate	0.46	0.07, 0.84	0.021	0.08	-0.39, 0.55	0.74	
Unfavourable	0.43	0.08, 0.78	0.016	0.25	-0.19, 0.68	0.26	
Non-Hodgkin lymphoma							0.67
Intermediate	0.59	0.21, 0.97	0.0023	0.20	-0.26, 0.66	0.40	

Unfavourable	0.51	0.13, 0.89	0.0090	-0.08	-0.56, 0.39	0.74	
Kidney cancer							0.0049
Intermediate	-0.37	-1.47, 0.72	0.50	-0.34	-1.46, 0.78	0.55	
Unfavourable	-0.12	-1.11, 0.87	0.81	0.76	-0.22, 1.73	0.13	
Uterine cancer							0.098
Intermediate	0.69	-0.06, 1.44	0.073	0.14	-0.74, 1.03	0.75	
Unfavourable	0.92	0.06, 1.79	0.037	-0.04	-1.02, 0.95	0.94	
Pancreatic cancer							0.0002
Intermediate	0.38	-0.68, 1.44	0.48	0.48	-0.68, 1.65	0.42	
Unfavourable	0.70	-0.34, 1.74	0.19	1.55	0.33, 2.77	0.013	
Bladder cancer							0.0002
Intermediate	0.07	-0.81, 0.96	0.87	0.31	-0.55, 1.17	0.48	
Unfavourable	0.73	-0.14, 1.59	0.099	1.12	0.25, 1.99	0.012	
Oral cavity/pharyngeal cancer							0.73
Intermediate	0.57	-0.03, 1.17	0.061	0.13	-0.53, 0.79	0.69	
Unfavourable	0.44	-0.18, 1.06	0.17	0.10	-0.58, 0.78	0.77	
Ovarian cancer							0.27
Intermediate	0.08	-0.62, 0.78	0.81	0.65	-0.03, 1.33	0.060	
Unfavourable	0.15	-0.56, 0.85	0.69	0.44	-0.24, 1.12	0.21	
Lymphocytic leukaemia							0.69
Intermediate	-0.36	-1.42, 0.69	0.50	0.95	-0.14, 2.04	0.086	
Unfavourable	-0.40	-1.43, 0.64	0.45	0.49	-0.53, 1.51	0.35	

Overall cancer = overall incident cases of the 13 cancer types assessed in this study

Cox proportional hazards regression models adjusted for age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries, Townsend Index, education, birth location, and income

References

1. Alcohol Change UK. Alcohol units. Accessed February 23, 2021. <https://alcoholchange.org.uk/alcohol-facts/interactive-tools/check-your-drinking/alcohol-units>.
2. The IPAQ Group. Guidelines for the data processing and analysis of the International Physical Activity Questionnaire (IPAQ) – short and long forms. Accessed February 25, 2021. <https://www.researchgate.net/file.PostFileLoader.html?id=5641f4c36143250eac8b45b7&assetKey=AS%3A294237418606593%401447163075131>.